Results 51 to 60 of about 72,525 (247)

Leveraging Microphysiological Systems to Facilitate Neutrophil‐Based Cancer Immunotherapy

Advanced Science, EarlyView.
Microphysiological systems are emerging as powerful human‐relevant platforms for studying neutrophil biology in cancer. Current applications of spheroids, organoids, and organ‐on‐a‐chip models are reviewed, together with future opportunities in behaviorome profiling, multi‐omics integration, personalized medicine, immune crosstalk, and multi‐organ ...
Shuai Shao, Markus Isfeld Diehl, Caroline N. Jones   +2 more
wiley   +1 more source

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters [PDF]

, 2009
Imatinib mesylate and nilotinib are highly effective at eradicating the majority of chronic myeloid leukemia (CML) cells; however, neither agent induces apoptosis of primitive CML CD34⁺ cells.
Holyoake, T.L., Davies, A., Jordanides, N.E., Giannoudis, A., Jorgensen, H.G., Harris, R.J., Hatziieremia, S., Mountford, J.C., Pirmohamed, M., Clark, R.E., Lucas, C.M.   +10 more
core   +2 more sources

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Periorbital edema secondary to imatinib mesylate [PDF]

, 2010
Collin M McClelland, George J Harocopos, Philip L CusterSchool of Medicine, Washington University, St. Louis, MO, USAAbstract: Imatinib mesylate (Gleevec®) is a well-established pharmacologic treatment for all phases of chronic myeloid leukemia ...
Philip L Custer, Custer, Philip L, McClelland, Collin M, George J Harocopos, Harocopos, George J, Collin M McClelland   +5 more
core   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation [PDF]

, 2012
The mitochondrial respiratory chain (MRC) consists of protein complexes I, II, III, IV and V that support oxidative phosphorylation (OXPHOS), which depends on electron transport to generate adenosine triphosphate (ATP).
Flis, Krzysztof, Skorski, Tomasz, Bhatia, Ravi, Irvine, David, Bhatia, R., Copland, Mhairi, Irvine, D., Copland, M., Skorski, T., Flis, K.   +9 more
core   +1 more source

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen, Mathilde Rønne Koch, Cecilie Utke Rank, Christen Lykkegaard Andersen, Allan Weimann, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Flemming Nielsen, Tore Bjerregaard Stage, Sara Bisgaard Jensen, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff   +14 more
wiley   +1 more source

Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity

Acta Medica Alanya, 2020
Aim: Imatinib mesylate is a tyrosine kinase inhibitor and is approved as a standard first-line therapy of chronic myeloid leukemia. Oxidative stress, as well as intracellular calcium overload and mitochondrial dysfunction, play an important role in ...
İshak Suat Övey, Can Ramazan Öncel
doaj  

In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells

BMC Cancer, 2010
Background Breast cancer treatment is based on a combination of adjuvant chemotherapy followed by radiotherapy effecting intracellular signal transduction. With the tyrosine kinase inhibitors new targeted drugs are available.
Weigel Marion T, Dahmke Linda, Schem Christian, Bauerschlag Dirk O, Weber Katrin, Niehoff Peter, Bauer Maret, Strauss Alexander, Jonat Walter, Maass Nicolai, Mundhenke Christoph   +10 more
doaj   +1 more source

Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor [PDF]

Yeungnam University Journal of Medicine, 2019
Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare.
Min Kyu Kang, Heon Ju Lee, Joon Hyuk Choi   +2 more
doaj   +1 more source